Literature DB >> 6458673

Diffusion of moxalactam into the cerebrospinal fluid in children with bacterial meningitis.

M C Thirumoorthi, J A Buckley, M K Aravind, R E Kauffman, A S Dajani.   

Abstract

We studied the penetration of moxalactam into the cerebrospinal fluid of 16 children (age range one month to 4 1/2 years) who were being treated for bacterial meningitis. Two hours after single intravenous doses of 15 or 25 mg/kg, moxalactam was detectable in the CSF in only one of 11 instances; however, following three doses (50 mg/kg each) moxalactam was detectable in eight of 17 instances. In these eight instances CSF concentrations of moxalactam ranged between 1.5 and 18.9 micrograms/ml (mean 7.7) and the CSF/plasma ratio ranged from 2.6 to 36% (mean 17.7). There was no relation between the stage of meningitis or the CSF cell count and the diffusion of the drug into the CSF. However, the diffusion of the drug significantly correlated with the CSF protein content. In view of the unpredictability of moxalactam penetration into CSF, caution should be exercised in using it alone in the treatment of meningitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458673     DOI: 10.1016/s0022-3476(81)80036-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Antimicrobial therapy in newborn infants.

Authors:  M Bhat
Journal:  Indian J Pediatr       Date:  1983 Mar-Apr       Impact factor: 1.967

2.  Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients.

Authors:  R J Creger; R I Cowan; H S Nearman; J L Blumer; W R Selman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pharmacokinetics of cefoperazone in full-term and premature neonates.

Authors:  W N Rosenfeld; H E Evans; R Batheja; R C Jhaveri; K Vohra; A J Khan
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 5.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

6.  Moxalactam pharmacokinetics in children.

Authors:  M F Romagnoli; K Flynn; G R Siber; D A Goldmann
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.